중동 및 아프리카의 체외진단 시장 규모 및 예측(2021-2034년) : 세계 및 지역별 점유율, 동향, 성장 기회 분석 보고서 범위 - 제품, 기술, 용도, 편리성, 최종사용자 및 지역별

According to our new research study on "Middle East & Africa in-vitro diagnostic market forecast to 2034 -Regional Analysis - by Product, Technology, Application, Usability, Site of Testing, Specimen, and End User," the market is anticipated to grow from US$ 3.89 billion in 2025 to US$ 7.24 billion by 2034; the market is expected to register a CAGR of 7.2% from 2026 to 2034. Middle East & Africa In-Vitro Diagnostic market growth is attributed to the rising prevalence of chronic noncommunicable diseases, persistent infectious disease burden, health system strengthening, and public health surveillance expansion.

Governments and international health agencies have prioritized strengthening laboratory networks to manage chronic and infectious disease challenges. PublicHO African Region's progress reporting on noncommunicable diseases and public health indicates strong emphasis on early diagnosis and integrated care, which requires laboratory diagnostic infrastructure and standardized testing protocols to reach targets for disease control and prevention. Enhanced surveillance systems for communicable diseases, including HIV, cholera, and routine vaccine-preventable diseases, rely on diagnostic testing to inform public health responses. According to the WHO HIV/AIDS fact sheet, while at the global level 40.8 million people were living with HIV at the end of 2024, continued efforts to diagnose, treat, and suppress viral load through laboratory testing remain central to controlling the epidemic. Multi-country outbreaks of cholera in Africa and the Eastern Mediterranean stimulate investment in laboratory preparedness, rapid diagnostic test (RDT) stockpiles, and quality assurance programs to support early case detection and response planning, as documented in WHO outbreak situation reports from 2023-2024. As health systems expand coverage and surveillance sophistication, routine lab testing becomes embedded in primary care and national disease programs, increasing demand for an array of IVD products from basic clinical chemistry to advanced molecular diagnostics.

Middle East & Africa In-Vitro Diagnostic market is categorized into the Saudi Arabia, South Africa, UAE, and the Rest of Middle East & Africa. According to the International Diabetes Federation, in 2024, approximately 20.7 % of UAE adults (nearly 1.27 million people) were living with diabetes, a persistently high national prevalence that necessitates regular blood glucose and related biomarker testing. Large segments of the population are at risk of metabolic and cardiovascular complications linked to diabetes and obesity, with lifestyle risk factors such as being overweight present at elevated levels, driving demand for panel testing and monitoring. Government health authorities have responded with robust National Prediabetes and Diabetes Screening campaigns. The Ministry of Health and Prevention (MoHAP) exceeded its early-detection target by conducting over 150,000 screening tests in a year under the Government Accelerators Programme, emphasizing widespread use of HbA1c and other diagnostic assays. In addition to diabetes efforts, routine screening for infectious diseases, cardiovascular markers, cancer biomarkers, and genetic conditions are integrated into preventive care pathways, reflecting a strategic shift toward early diagnosis. The combination of high chronic disease prevalence, structured national screening initiatives, and the integration of molecular, point-of-care, and automation-enabled IVD platforms is therefore driving heightened utilization of in-vitro diagnostics across clinical settings in the UAE.

According to 2024 mid-year estimates by Statistics South Africa, approximately 8.0 million people in South Africa are living with HIV, with 12.7 % overall national prevalence and 16.68 % among adults aged 15-49, maintaining significant demand for HIV testing, monitoring, and related IVD assays. According to the World Health Organization (WHO), South Africa continues to face a high tuberculosis incidence of 427 per 100,000 population in 2023, and over half of TB patients also have HIV, reinforcing the need for combined infectious disease diagnostics, including rapid molecular tests and point-of-care screening.

Chronic non-communicable diseases such as diabetes and cardiovascular conditions are increasing, with government health data indicating that diabetes remains one of the leading causes of death and has risen as a proportion of mortality, particularly among women. This combined disease burden expands demand for biochemical and molecular diagnostics across public and private sectors. The government has prioritized early detection and prevention, strengthening national health screening programs and laboratory networks that drive IVD utilization.

Technological advancements such as PCR, next-generation sequencing, and point-of-care diagnostics are being implemented in clinical settings, improving the speed and accuracy of diagnoses for infectious and chronic diseases alike. Partnerships between global diagnostic manufacturers and local healthcare institutions are enhancing access to modern IVD platforms tailored to South Africa's epidemiological profile.

Thus, the high prevalence of communicable and non-communicable diseases, government screening initiatives, and adoption of advanced testing technologies are key factors driving the market expansion in South Africa.

The US Food and Drug Administration, National Institute of Health, are among the primary and secondary sources referred to while preparing the Middle East & Africa in-vitro diagnostic market report.

Table Of Contents

1. Executive Summary

• 1.1 Analyst Market Outlook
• 1.2 Market Attractiveness

2. Middle East and Africa In-Vitro Diagnostic Market Landscape

• 2.1 Overview
• 2.2 Value Chain Analysis
  • 2.2.1 Raw Material Suppliers / Components
  • 2.2.2 Manufacturers/ Process / Technology
  • 2.2.3 Distribution Landscape
• 2.3 Supply Chain Analysis
  • 2.3.1 List of Manufacturers/Suppliers
  • 2.3.2 List of Potential Customers (Upto 50)
• 2.4 Porter's Five Force Analysis
  • 2.4.1 Bargaining Power of Suppliers:
  • 2.4.2 Bargaining Power of Buyers:
  • 2.4.3 Threat of New Entrants:
  • 2.4.4 Threat of Substitutes:
  • 2.4.5 Competitive Rivalry:
• 2.5 PEST Analysis
• 2.6 Import Analysis- China/Europe
  • 2.6.1 Import Analysis- China/Europe
  • 2.6.2 Export Analysis- China/Europe
• 2.7 Impact of Artificial Intelligence (AI)
  • 2.7.1 AI Transforming Diagnostic Capabilities in IVD
  • 2.7.2 Regional Focus & Strategic Initiatives
  • 2.7.3 Emerging AI Applications in IVD
  • 2.7.4 Key Drivers Behind Adoption
• 2.8 Product or Technology Roadmap
  • 2.8.1 Early Phase (2001-2010): Digital Systems & Core Lab Technology Adoption
  • 2.8.2 Growth & Molecular Shift (2011-2020): PCR, POC & Genetic Testing
  • 2.8.3 Digital & AI-Enabled Integration (2021-2026): Smart, Connected Diagnostics
  • 2.8.4 Outlook (2027-2035): Precision Medicine & Population-Scale Diagnostics
• 2.9 Sustainability and ESG Trends
  • 2.9.1 Environmental Sustainability: Reducing Impact Across the Value Chain
  • 2.9.2 Social Responsibility: Expanding Access, Equity & Workforce Inclusion
  • 2.9.3 Governance: Transparency, Reporting & Accountability
  • 2.9.4 Emerging Themes & Regional Drivers
• 2.10 Regulatory Framework
• 2.11 Average Selling Price, 2024
  • 2.11.1 By Products, 2024
    • 2.11.1.1 Reagents & Kits
    • 2.11.1.2 Manual & Low-Automation Instruments
    • 2.11.1.3 Semi-Automated Instruments
    • 2.11.1.4 Fully Automated Instruments
  • 2.11.2 By End Users, 2024
    • 2.11.2.1 Reagents & Kits
    • 2.11.2.2 Manual & Low-Automation Instruments
    • 2.11.2.3 Semi-Automated Instruments
    • 2.11.2.4 Fully Automated Instruments
• 2.12 Prevalence of Key Disease Indications
• 2.13 Reimbursement Scenarios
  • 2.13.1 Formal Reimbursement Policies - Limited & Fragmented
  • 2.13.2 Public Insurance Coverage - General Lab Services, Not Test-Specific
  • 2.13.3 Private Insurance - Variable & Plan-Dependent
  • 2.13.4 Health Technology Assessment (HTA) - Emerging but Immature
  • 2.13.5 Tender-Based Procurement - Dominant in Public Sector
• 2.14 Manufacturing & Retail Pricing of Key 10 Brands
• 2.15 Company Analysis, By Trade and Tender
  • 2.15.1 Strategic Implications for Companies
• 2.16 Tender Certifications Data
• 2.17 Sales Volume of Key Instruments, 2025

3. Competitive Landscape

• 3.1 Company Benchmarking by Key Players
• 3.2 Key Company Analysis- By Segments, 2024
• 3.3 Market Share Analysis, 2025 - By Key Players (%)
  • 3.3.1 By Key Players, 2024 (%)
  • 3.3.2 By Key Products, 2024 (%)
    • 3.3.2.1 Product Category
    • 3.3.2.2 Product Brands
• 3.4 Market Concentration
• 3.5 VOC Feedback in MEA IVD Market

4. Middle East and Africa In-Vitro Diagnostic Market - Key Industry Dynamics

• 4.1 Market Drivers
  • 4.1.1 Rising Prevalence of Chronic Noncommunicable Diseases
  • 4.1.2 Persistent Infectious Disease Burden
  • 4.1.3 Health System Strengthening and Public Health Surveillance Expansion
• 4.2 Market Restraints
  • 4.2.1 Limited Healthcare Infrastructure and Diagnostic Capacity
  • 4.2.2 Shortage of Skilled Healthcare Workforce and Laboratory Professionals
  • 4.2.3 Fragmented Regulatory Frameworks and Limited Access to Quality Diagnostics
• 4.3 Market Opportunities
  • 4.3.1 Integration of Laboratory Networks
  • 4.3.2 Diagnostics for HIV
  • 4.3.3 Malaria Diagnostics
• 4.4 Future Trends
  • 4.4.1 Increasing Adoption of Point-of-Care Testing
  • 4.4.2 Growth in Molecular Diagnostics and Personalized Medicine
  • 4.4.3 Digitalization and AI Integration in Diagnostics
• 4.5 Impact of Drivers and Restraints

5. Middle East and Africa In-Vitro Diagnostic Market - Region Market Analysis

• 5.1 Middle East and Africa In-Vitro Diagnostic Market Overview
• 5.2 Middle East and Africa In-Vitro Diagnostic Market Revenue (US$ Million), 2021-2034
• 5.3 Middle East and Africa In-Vitro Diagnostic Market Forecast and Analysis

6. Middle East and Africa In-Vitro Diagnostic Market Revenue Analysis - Product

• 6.1 List of Key Players in Product Market, (US$)
  • 6.1.1 Reagents and Kits
    • 6.1.1.1 Overview
    • 6.1.1.2 Reagents and Kits: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 6.1.2 Instruments
    • 6.1.2.1 Overview
    • 6.1.2.2 Instruments: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
      • 6.1.2.2.1 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Instruments
        • 6.1.2.2.1.1 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Clinical Chemistry Analyzers
          • 6.1.2.2.1.1.1 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Automated Clinical Chemistry Analyzers
        • 6.1.2.2.1.2 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Immunoassay Instruments
          • 6.1.2.2.1.2.1 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by ELISA Systems
          • 6.1.2.2.1.2.2 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Fluorescent Immunoassay Analyzers
        • 6.1.2.2.1.3 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Hematology and Coagulation Analyzers
          • 6.1.2.2.1.3.1 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Blood Cell Morphology Analyzers
          • 6.1.2.2.1.3.2 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by ESR Analyzers
          • 6.1.2.2.1.3.3 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Coagulation Analyzers
        • 6.1.2.2.1.4 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Urinalysis Instruments
  • 6.1.3 Software and Services
    • 6.1.3.1 Overview
    • 6.1.3.2 Software and Services: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)

7. Middle East and Africa In-Vitro Diagnostic Market Revenue Analysis -Technology

• 7.1 List of Key Players in Technology Market, (US$)
  • 7.1.1 Immunoassay or Immunochemistry
    • 7.1.1.1 Overview
    • 7.1.1.2 Immunoassay or Immunochemistry: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
      • 7.1.1.2.1 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Immunoassay or Immunochemistry
        • 7.1.1.2.1.1 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Enzyme-linked Immunosorbent Assay (ELISA)
          • 7.1.1.2.1.1.1 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Blood Banking ELISA
        • 7.1.1.2.1.2 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Fluorescent Immunoassay (FIA)
        • 7.1.1.2.1.3 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Latex Agglutination
        • 7.1.1.2.1.4 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Turbidimetry
  • 7.1.2 Immunochromatography
    • 7.1.2.1 Overview
    • 7.1.2.2 Immunochromatography: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
      • 7.1.2.2.1 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Immunochromatography
  • 7.1.3 Cellular analysis
    • 7.1.3.1 Overview
    • 7.1.3.2 Cellular analysis: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
      • 7.1.3.2.1 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Cellular Analysis
  • 7.1.4 Proteomic or metabolomic
    • 7.1.4.1 Overview
    • 7.1.4.2 Proteomic or metabolomic: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 7.1.5 Sensor technology
    • 7.1.5.1 Overview
    • 7.1.5.2 Sensor technology: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
      • 7.1.5.2.1 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Sensor Technology
  • 7.1.6 Miniaturized systems
    • 7.1.6.1 Overview
    • 7.1.6.2 Miniaturized systems: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 7.1.7 Multiplex technology
    • 7.1.7.1 Overview
    • 7.1.7.2 Multiplex technology: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 7.1.8 Optical detection
    • 7.1.8.1 Overview
    • 7.1.8.2 Optical detection: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 7.1.9 Electrochemical analysis
    • 7.1.9.1 Overview
    • 7.1.9.2 Electrochemical analysis: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 7.1.10 Separation technology
    • 7.1.10.1 Overview
    • 7.1.10.2 Separation technology: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
      • 7.1.10.2.1 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Separation Technology
  • 7.1.11 Molecular Diagnosis
    • 7.1.11.1 Overview
    • 7.1.11.2 Molecular Diagnosis: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
      • 7.1.11.2.1 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Molecular Diagnosis
  • 7.1.12 Analytical Chemistry
    • 7.1.12.1 Overview
    • 7.1.12.2 Analytical chemistry: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 7.1.13 Molecular Amplification
    • 7.1.13.1 Overview
    • 7.1.13.2 Molecular amplification: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 7.1.14 Molecular Genomics
    • 7.1.14.1 Overview
    • 7.1.14.2 Molecular genomics: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
      • 7.1.14.2.1 Middle East and Africa In-Vitro Diagnostic Market Forecasts and Analysis by Molecular Genomics
  • 7.1.15 High-throughput molecular
    • 7.1.15.1 Overview
    • 7.1.15.2 High-throughput molecular: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 7.1.16 Genetic Analysis
    • 7.1.16.1 Overview
    • 7.1.16.2 Genetic Analysis: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)

8. Middle East and Africa In-Vitro Diagnostic Market Revenue Analysis -Application

• 8.1 List of Key Players in Application Market, (US$)
  • 8.1.1 Infectious Diseases
    • 8.1.1.1 Overview
    • 8.1.1.2 Infectious Diseases: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 8.1.2 Oncology
    • 8.1.2.1 Overview
    • 8.1.2.2 Oncology: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 8.1.3 Cardiology
    • 8.1.3.1 Overview
    • 8.1.3.2 Cardiology: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 8.1.4 Nephrology
    • 8.1.4.1 Overview
    • 8.1.4.2 Nephrology: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 8.1.5 Diabetes
    • 8.1.5.1 Overview
    • 8.1.5.2 Diabetes: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 8.1.6 Genetic Diseases
    • 8.1.6.1 Overview
    • 8.1.6.2 Genetic Diseases: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 8.1.7 Blood Grouping and Testing
    • 8.1.7.1 Overview
    • 8.1.7.2 Blood Grouping and Testing: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 8.1.8 Allergy Diagnostics
    • 8.1.8.1 Overview
    • 8.1.8.2 Allergy Diagnostics: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 8.1.9 Gastrointestinal Diseases
    • 8.1.9.1 Overview
    • 8.1.9.2 Gastrointestinal Diseases: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 8.1.10 Immune System Disorders
    • 8.1.10.1 Overview
    • 8.1.10.2 Immune System Disorders: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 8.1.11 Others
    • 8.1.11.1 Overview
    • 8.1.11.2 Others: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)

9. Middle East and Africa In-Vitro Diagnostic Market Revenue Analysis -Usability

• 9.1 List of Key Players in Usability Market, (US$)
  • 9.1.1 Disposable Devices
    • 9.1.1.1 Overview
    • 9.1.1.2 Disposable Devices: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 9.1.2 Reusable Equipment
    • 9.1.2.1 Overview
    • 9.1.2.2 Reusable Equipment: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)

10. Middle East and Africa In-Vitro Diagnostic Market Revenue Analysis -Site of Testing

• 10.1 List of Key Players in Site of Testing Market, (US$)
  • 10.1.1 Laboratory Tests
    • 10.1.1.1 Overview
    • 10.1.1.2 Laboratory Tests: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 10.1.2 Point of Care Tests
    • 10.1.2.1 Overview
    • 10.1.2.2 Point of Care Tests: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)

11. Middle East and Africa In-Vitro Diagnostic Market Revenue Analysis -Specimen

• 11.1 List of Key Players in Specimen Market, (US$)
  • 11.1.1 Blood Serum and Plasma
    • 11.1.1.1 Overview
    • 11.1.1.2 Blood Serum and Plasma: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 11.1.2 Saliva Specimens
    • 11.1.2.1 Overview
    • 11.1.2.2 Saliva Specimens: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 11.1.3 Urine Specimens
    • 11.1.3.1 Overview
    • 11.1.3.2 Urine Specimens: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 11.1.4 Others
    • 11.1.4.1 Overview
    • 11.1.4.2 Others: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)

12. Middle East and Africa In-Vitro Diagnostic Market Revenue Analysis - End User

• 12.1 List of Key Players in End User Market, (US$)
  • 12.1.1 Hospitals
    • 12.1.1.1 Overview
    • 12.1.1.2 Hospitals: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 12.1.2 Clinical Laboratories
    • 12.1.2.1 Overview
    • 12.1.2.2 Clinical Laboratories: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 12.1.3 Home Care
    • 12.1.3.1 Overview
    • 12.1.3.2 Home Care: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)
  • 12.1.4 Others
    • 12.1.4.1 Overview
    • 12.1.4.2 Others: Middle East and Africa In-Vitro Diagnostic Market - Revenue, 2021-2034 (US$ Million)

13. Middle East and Africa In-Vitro Diagnostic Market - Country Analysis

• 13.1 Middle East and Africa In-Vitro Diagnostic Market Breakdown by Countries
  • 13.1.1 South Africa Market
    • 13.1.1.1 South Africa: Middle East and Africa In-Vitro Diagnostic Market Revenue and Forecasts, 2021-2034 (US$ Million)
    • 13.1.1.2 South Africa: Middle East and Africa In-Vitro Diagnostic Market- By Segmentation
      • 13.1.1.2.1 Product
        • 13.1.1.2.1.1 Instruments
          • 13.1.1.2.1.1.1 Clinical Chemistry Analyzers
          • 13.1.1.2.1.1.1.1 Automated Clinical Chemistry Analyzers
          • 13.1.1.2.1.1.2 Immunoassay Instruments
          • 13.1.1.2.1.1.2.1 ELISA Systems
          • 13.1.1.2.1.1.3 Fluorescent Immunoassay Analyzers
          • 13.1.1.2.1.1.4 Hematology And Coagulation Analyzers
          • 13.1.1.2.1.1.4.1 Blood Cell Morphology Analyzers
          • 13.1.1.2.1.1.4.2 ESR Analyzers
          • 13.1.1.2.1.1.4.3 Coagulation Analyzers
          • 13.1.1.2.1.1.5 Urinalysis Instruments
      • 13.1.1.2.2 Technology
        • 13.1.1.2.2.1 Immunoassay Or Immunochemistry
          • 13.1.1.2.2.1.1 Enzyme-linked Immunosorbent Assay (ELISA)
          • 13.1.1.2.2.1.1.1 Blood Banking ELISA
          • 13.1.1.2.2.1.2 Fluorescent Immunoassay (FIA)
          • 13.1.1.2.2.1.3 Latex Agglutination
          • 13.1.1.2.2.1.4 Turbidimetry
        • 13.1.1.2.2.2 Immunochromatography
        • 13.1.1.2.2.3 Cellular Analysis
        • 13.1.1.2.2.4 Sensor Technology
        • 13.1.1.2.2.5 Separation Technology
        • 13.1.1.2.2.6 Molecular Diagnosis
        • 13.1.1.2.2.7 Molecular Genomics
      • 13.1.1.2.3 Application
      • 13.1.1.2.4 Usability
      • 13.1.1.2.5 Site Of Testing
      • 13.1.1.2.6 Specimen
      • 13.1.1.2.7 By End User
  • 13.1.2 Saudi Arabia Market
    • 13.1.2.1 Saudi Arabia: Middle East and Africa In-Vitro Diagnostic Market Revenue and Forecasts, 2021-2034 (US$ Million)
    • 13.1.2.2 Saudi Arabia: Middle East and Africa In-Vitro Diagnostic Market- By Segmentation
      • 13.1.2.2.1 Product
        • 13.1.2.2.1.1 Instruments
          • 13.1.2.2.1.1.1 Clinical Chemistry Analyzers
          • 13.1.2.2.1.1.1.1 Automated Clinical Chemistry Analyzers
          • 13.1.2.2.1.1.2 Immunoassay Instruments
          • 13.1.2.2.1.1.2.1 ELISA Systems
          • 13.1.2.2.1.1.2.2 Fluorescent Immunoassay Analyzers
          • 13.1.2.2.1.1.3 Hematology And Coagulation Analyzers
          • 13.1.2.2.1.1.3.1 Blood Cell Morphology Analyzers
          • 13.1.2.2.1.1.3.2 ESR Analyzers
          • 13.1.2.2.1.1.3.3 Coagulation Analyzers
          • 13.1.2.2.1.1.4 Urinalysis Instruments
        • 13.1.2.2.1.2 Technology
          • 13.1.2.2.1.2.1 Immunoassay Or Immunochemistry
          • 13.1.2.2.1.2.1.1 Enzyme-linked Immunosorbent Assay (ELISA)
          • 13.1.2.2.1.2.1.2 Blood Banking ELISA
          • 13.1.2.2.1.2.1.3 Fluorescent Immunoassay (FIA)
          • 13.1.2.2.1.2.1.4 Latex Agglutination
          • 13.1.2.2.1.2.1.5 Turbidimetry
          • 13.1.2.2.1.2.2 Immunochromatography
          • 13.1.2.2.1.2.3 Cellular Analysis
          • 13.1.2.2.1.2.4 Sensor Technology
          • 13.1.2.2.1.2.5 Separation Technology
          • 13.1.2.2.1.2.6 Molecular Diagnosis
          • 13.1.2.2.1.2.7 Molecular Genomics
        • 13.1.2.2.1.3 Application
        • 13.1.2.2.1.4 Usability
        • 13.1.2.2.1.5 Site Of Testing
        • 13.1.2.2.1.6 Specimen
        • 13.1.2.2.1.7 By End User
  • 13.1.3 UAE Market
    • 13.1.3.1 UAE: Middle East and Africa In-Vitro Diagnostic Market Revenue and Forecasts, 2021-2034 (US$ Million)
    • 13.1.3.2 UAE: Middle East and Africa In-Vitro Diagnostic Market- By Segmentation
      • 13.1.3.2.1 Product
        • 13.1.3.2.1.1 Instruments
          • 13.1.3.2.1.1.1 Clinical Chemistry Analyzers
          • 13.1.3.2.1.1.1.1 Automated Clinical Chemistry Analyzers
          • 13.1.3.2.1.1.2 Immunoassay Instruments
          • 13.1.3.2.1.1.2.1 ELISA Systems
          • 13.1.3.2.1.1.2.2 Fluorescent Immunoassay Analyzers
          • 13.1.3.2.1.1.3 Hematology And Coagulation Analyzers
          • 13.1.3.2.1.1.3.1 Blood Cell Morphology Analyzers
          • 13.1.3.2.1.1.3.2 ESR Analyzers
          • 13.1.3.2.1.1.3.3 Coagulation Analyzers
          • 13.1.3.2.1.1.4 Urinalysis Instruments
      • 13.1.3.2.2 Technology
        • 13.1.3.2.2.1 Immunoassay Or Immunochemistry
          • 13.1.3.2.2.1.1 Enzyme-linked Immunosorbent Assay (ELISA)
          • 13.1.3.2.2.1.1.1 Blood Banking ELISA
          • 13.1.3.2.2.1.2 Fluorescent Immunoassay (FIA)
          • 13.1.3.2.2.1.3 Latex Agglutination
          • 13.1.3.2.2.1.4 Turbidimetry
        • 13.1.3.2.2.2 Immunochromatography
        • 13.1.3.2.2.3 Cellular Analysis
        • 13.1.3.2.2.4 Sensor Technology
        • 13.1.3.2.2.5 Separation Technology
        • 13.1.3.2.2.6 Molecular Diagnosis
        • 13.1.3.2.2.7 Molecular Genomics
      • 13.1.3.2.3 Application
      • 13.1.3.2.4 Usability
      • 13.1.3.2.5 Site Of Testing
      • 13.1.3.2.6 Specimen
      • 13.1.3.2.7 By End User
  • 13.1.4 Rest of MEA Market
    • 13.1.4.1 Rest of MEA: Middle East and Africa In-Vitro Diagnostic Market Revenue and Forecasts, 2021-2034 (US$ Million)
    • 13.1.4.2 Rest of MEA: Middle East and Africa In-Vitro Diagnostic Market- By Segmentation
      • 13.1.4.2.1 Product
        • 13.1.4.2.1.1 Instruments
          • 13.1.4.2.1.1.1 Clinical Chemistry Analyzers
          • 13.1.4.2.1.1.1.1 Automated Clinical Chemistry Analyzers
          • 13.1.4.2.1.1.2 Immunoassay Instruments
          • 13.1.4.2.1.1.2.1 ELISA Systems
          • 13.1.4.2.1.1.3 Fluorescent Immunoassay Analyzers
          • 13.1.4.2.1.1.4 Hematology And Coagulation Analyzers
          • 13.1.4.2.1.1.4.1 Blood Cell Morphology Analyzers
          • 13.1.4.2.1.1.4.2 ESR Analyzers
          • 13.1.4.2.1.1.4.3 Coagulation Analyzers
          • 13.1.4.2.1.1.5 Urinalysis Instruments
      • 13.1.4.2.2 Technology
        • 13.1.4.2.2.1 Immunoassay Or Immunochemistry
          • 13.1.4.2.2.1.1 Enzyme-linked Immunosorbent Assay (ELISA)
          • 13.1.4.2.2.1.1.1 Blood Banking ELISA
          • 13.1.4.2.2.1.2 Fluorescent Immunoassay (FIA)
          • 13.1.4.2.2.1.3 Latex Agglutination
          • 13.1.4.2.2.1.4 Turbidimetry
        • 13.1.4.2.2.2 Immunochromatography
        • 13.1.4.2.2.3 Cellular Analysis
        • 13.1.4.2.2.4 Sensor Technology
        • 13.1.4.2.2.5 Separation Technology
        • 13.1.4.2.2.6 Molecular Diagnosis
        • 13.1.4.2.2.7 Molecular Genomics
      • 13.1.4.2.3 Application
      • 13.1.4.2.4 Usability
      • 13.1.4.2.5 Site Of Testing
      • 13.1.4.2.6 Specimen
      • 13.1.4.2.7 By End User

14. Middle East and Africa In-Vitro Diagnostic Market Industry Landscape

• 14.1 List of Key 20 Global Players
• 14.2 List of Key 20 End Users in MEA In-Vitro Diagnostic Market

15. Middle East and Africa In-Vitro Diagnostic Market - Key Company Profiles

• 15.1 Abbott
  • 15.1.1 Key Facts
  • 15.1.2 Business Description
  • 15.1.3 Products and Services
  • 15.1.4 Financial Overview
  • 15.1.5 SWOT Analysis
  • 15.1.6 Key Developments
• 15.2 F. Hoffmann-La Roche Ltd
  • 15.2.1 Key Facts
  • 15.2.2 Business Description
  • 15.2.3 Products and Services
  • 15.2.4 Financial Overview
  • 15.2.5 SWOT Analysis
  • 15.2.6 Key Developments
• 15.3 Danaher Corp
  • 15.3.1 Key Facts
  • 15.3.2 Business Description
  • 15.3.3 Products and Services
  • 15.3.4 Financial Overview
  • 15.3.5 SWOT Analysis
  • 15.3.6 Key Developments
• 15.4 Siemens AG
  • 15.4.1 Key Facts
  • 15.4.2 Business Description
  • 15.4.3 Products and Services
  • 15.4.4 Financial Overview
  • 15.4.5 SWOT Analysis
  • 15.4.6 Key Developments
• 15.5 Becton Dickinson and Co
  • 15.5.1 Key Facts
  • 15.5.2 Business Description
  • 15.5.3 Products and Services
  • 15.5.4 Financial Overview
  • 15.5.5 SWOT Analysis
  • 15.5.6 Key Developments
• 15.6 Sysmex Corp
  • 15.6.1 Key Facts
  • 15.6.2 Business Description
  • 15.6.3 Products and Services
  • 15.6.4 Financial Overview
  • 15.6.5 SWOT Analysis
  • 15.6.6 Key Developments
• 15.7 Bio-Rad Laboratories Inc
  • 15.7.1 Key Facts
  • 15.7.2 Business Description
  • 15.7.3 Products and Services
  • 15.7.4 Financial Overview
  • 15.7.5 SWOT Analysis
  • 15.7.6 Key Developments
• 15.8 bioMerieux SA
  • 15.8.1 Key Facts
  • 15.8.2 Business Description
  • 15.8.3 Products and Services
  • 15.8.4 Financial Overview
  • 15.8.5 SWOT Analysis
  • 15.8.6 Key Developments
• 15.9 DiaSorin SpA
  • 15.9.1 Key Facts
  • 15.9.2 Business Description
  • 15.9.3 Products and Services
  • 15.9.4 Financial Overview
  • 15.9.5 SWOT Analysis
  • 15.9.6 Key Developments
• 15.10 QuidelOrtho Corp
  • 15.10.1 Key Facts
  • 15.10.2 Business Description
  • 15.10.3 Products and Services
  • 15.10.4 Financial Overview
  • 15.10.5 SWOT Analysis
  • 15.10.6 Key Developments
• 15.11 ARKRAY Inc
  • 15.11.1 Key Facts
  • 15.11.2 Business Description
  • 15.11.3 Products and Services
  • 15.11.4 Financial Overview
  • 15.11.5 SWOT Analysis
  • 15.11.6 Key Developments
• 15.12 BioSystems
  • 15.12.1 Key Facts
  • 15.12.2 Business Description
  • 15.12.3 Products and Services
  • 15.12.4 Financial Overview
  • 15.12.5 SWOT Analysis
  • 15.12.6 Key Developments
• 15.13 Shenzhen New Industries Biomedical Engineering Co., Ltd.
  • 15.13.1 Key Facts
  • 15.13.2 Business Description
  • 15.13.3 Products and Services
  • 15.13.4 Financial Overview
  • 15.13.5 SWOT Analysis
  • 15.13.6 Key Developments
• 15.14 Werfen SA
  • 15.14.1 Key Facts
  • 15.14.2 Business Description
  • 15.14.3 Products and Services
  • 15.14.4 Financial Overview
  • 15.14.5 SWOT Analysis
  • 15.14.6 Key Developments
• 15.15 Diagnostica Stago, Inc
  • 15.15.1 Key Facts
  • 15.15.2 Business Description
  • 15.15.3 Products and Services
  • 15.15.4 Financial Overview
  • 15.15.5 SWOT Analysis
  • 15.15.6 Key Developments

16. Appendix

• 16.1 Glossary
• 16.2 Research Methodology and Approach
  • 16.2.1 Secondary Research
  • 16.2.2 Primary Research
  • 16.2.3 Market Estimation Approach
    • 16.2.3.1 Supply Side Analysis
    • 16.2.3.2 Demand Side Analysis
  • 16.2.4 Research Assumptions and Limitations
  • 16.2.5 Currency Conversion
• 16.2 About The Insight Partners
• 16.2 Market Intelligence Cloud